Does Contactless Vitals Tech Need FDA Clearance?

The question of whether a camera-based vital signs feature triggers regulatory review is the single most common reason hardware roadmaps stall before a prototype is built. Teams scoping a kiosk or embedded device often assume the worst, that any pulse reading from a camera automatically becomes a regulated diagnostic instrument, and they shelve the feature rather than wade into the paperwork. The reality is more structured than the fear suggests. Whether you need FDA clearance contactless vitals depends almost entirely on intended use and the claims printed on the screen, not on the underlying remote photoplethysmography (rPPG) physics. The same camera and the same algorithm can sit on either side of the regulatory line, and the deciding factor is what your product tells the user it is for.

The US Food and Drug Administration created a dedicated product classification in 2023 for "software for optical camera-based measurement of pulse rate, heart rate, breathing rate, and/or respiratory rate," placing it in Class II with special controls and confirming that contactless vitals is now a defined, clearable device category rather than a regulatory gray zone.

What FDA clearance for contactless vitals actually hinges on

The framework rests on the statutory definition of a medical device. Under the Federal Food, Drug, and Cosmetic Act, a product becomes a device when it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. The FDA reads intended use from your labeling, your marketing, and your user interface. This is why two physically identical contactless vitals devices can have completely different obligations.

The FDA's General Wellness: Policy for Low Risk Devices guidance draws the practical boundary. A product that makes a general wellness claim, encourages relaxation, fitness awareness, or healthy lifestyle habits, and poses a low risk to users, generally falls outside active device regulation. A product that claims to detect, diagnose, or monitor a specific condition, or that feeds a reading into a clinical decision, sits inside it.

For an embedded rPPG engine, the determining questions are concrete:

• Does the device display a number framed as a clinical measurement, or as a wellness estimate?
• Is the reading used to triage, screen for, or flag a medical condition?
• Does the labeling reference accuracy against a clinical reference standard?
• Is a clinician or care workflow relying on the output to make a decision?
• Is the population vulnerable, for example acute-care patients rather than gym members?

Answering yes to the diagnostic and clinical questions pushes a product toward Class II and a required submission. Staying strictly inside lifestyle and awareness framing keeps it under the general wellness umbrella.

Wellness positioning vs. cleared medical device

The table below maps the two paths most device makers actually choose between when planning medical device camera vitals regulation strategy.

Dimension	Wellness Positioning	Cleared Medical Device
Regulatory basis	FDA General Wellness Policy (low-risk)	FDC Act device definition, Class II
Typical claim	"Estimated heart rate for fitness awareness"	"Measures pulse rate for clinical use"
Submission required	No premarket submission	510(k) or De Novo
Intended environment	Gym, retail, home, smart display	Clinic, hospital, telehealth, kiosk triage
Quality system	Recommended, not mandated	Mandatory QMS (21 CFR Part 820)
Clinical validation	Optional internal testing	Required bench and human-subject data
Time to market	Weeks to months	Many months to over a year
Liability exposure	Lower, bounded by disclaimers	Higher, with reporting duties
Reimbursement potential	None	Possible with cleared indication

The wellness route is faster and cheaper, but it caps what you can claim and forecloses clinical reimbursement. The cleared route is slower and capital-intensive, but it unlocks hospital procurement, telehealth integration, and the ability to position the device as a measurement instrument rather than an estimate.

Industry applications and where the line falls

Clinical kiosks and waiting room screening

Clinical kiosk health screening compliance is where the distinction gets sharpest. A kiosk that captures vitals before a clinician encounter, displays them to staff, and informs triage is functioning as a measurement device. If the readings influence care, wellness framing will not hold, and a Class II pathway is the realistic plan. A retail kiosk that shows a user their estimated heart rate as a self-awareness tool can remain in the wellness category, provided the interface and signage avoid diagnostic language.

Fitness, smart displays, and consumer iot

Gym check-in screens, smart mirrors, and consumer tablets are the natural home of wellness positioning. The audience is general population, the use is informational, and the risk is low. These deployments can ship without a submission as long as the product avoids condition-specific claims such as detecting arrhythmia or hypertension.

Hospital and acute monitoring

Any device feeding continuous vitals into patient monitoring for acute-care populations is squarely a medical device. The patient population is vulnerable, the clinical stakes are high, and the wellness exemption is unavailable. Contactless vitals device approval here means a cleared indication for use, validated against reference monitors.

Current research and evidence

The clearest signal that contactless vitals has matured into a defined regulatory category came from the FDA itself. In 2023 the agency published a classification in the Federal Register for software performing optical camera-based measurement of pulse rate, heart rate, breathing rate, and respiratory rate, designating it Class II with special controls. That action created a predictable pathway where one previously did not exist.

A growing roster of cleared products demonstrates the route is navigable:

• Oxehealth received a De Novo authorization in 2021 for a vision-based patient monitoring platform measuring heart rate and breathing from an overhead camera, establishing the predicate that later submissions could reference.
• PanopticAI obtained 510(k) clearance in June 2023 for a smartphone-camera application measuring pulse rate in roughly 30 seconds using rPPG.
• FaceHeart secured 510(k) clearance in October 2023 for video-based contactless heart rate measurement as Class II Software as a Medical Device, with a subsequent clearance covering respiratory rate.
• Sleepiz received 510(k) clearance in December 2023 for a contactless device extracting respiration and heart rate from micro-motion.

The progression from a De Novo grant in 2021 to multiple 510(k) clearances in 2023 matters for planning. Once the De Novo established a classification, later entrants could pursue the faster 510(k) route by citing a legally marketed predicate, which compresses both timeline and cost relative to a first-of-kind submission.

The future of contactless vitals regulation

Three trends are shaping where this goes. First, the special-controls classification will keep lowering the barrier for 510(k) submissions because the predicate base is widening each year. Second, expect tighter FDA attention to algorithm transparency and demographic performance, particularly across skin tones, where rPPG signal quality varies and special controls increasingly call for representative validation data. Third, the line between wellness and clinical claims will be policed more actively as contactless features proliferate on consumer hardware, which raises the importance of disciplined labeling for any device maker hoping to stay in the wellness lane.

For embedded device builders, the strategic takeaway is that regulatory status is a product-design decision made early, not a problem discovered late. Choosing wellness or clinical positioning at the architecture stage determines your quality system, your validation budget, and your claims, and retrofitting that choice after launch is expensive.

Frequently asked questions

Does every camera that measures heart rate need FDA clearance? No. Clearance is tied to intended use, not the technology. A camera measuring heart rate for general fitness awareness can operate under the FDA General Wellness Policy. The same camera marketed to diagnose, screen, or monitor a medical condition becomes a Class II device requiring a 510(k) or De Novo submission.

What is the difference between 510(k) and De Novo for contactless vitals? A 510(k) demonstrates substantial equivalence to a legally marketed predicate device, which is now possible because of clearances since 2021. De Novo is used when no suitable predicate exists and creates a new classification. With the 2023 special-controls category established, most new contactless vitals products pursue the 510(k) route.

Can wellness positioning protect a clinical kiosk from regulation? Generally no. If a kiosk's vitals readings inform triage or clinical decisions for patients, the FDA treats it as a medical device regardless of disclaimers. Wellness positioning works only when claims, interface, and use stay within low-risk lifestyle and awareness framing.

Who is responsible for clearance, the algorithm vendor or the device maker? Responsibility attaches to the legal manufacturer placing the finished device on the market with a medical claim. An embedded rPPG engine can be supplied with validation documentation and a quality system that support the device maker's submission, but the finished-device manufacturer typically holds the clearance.

Circadify is building its embedded rPPG engine for exactly this decision point, with documentation and quality-system support designed to fit either a wellness deployment or a Class II submission depending on your product's intended use. Device makers and kiosk manufacturers planning a compliance-ready build can review the hardware integration guide at circadify.com/custom-builds/clinical-kiosks to scope the regulatory and engineering path together.